By inhibiting MEK activity, selumetinib disrupts downstream signaling, thereby inhibiting tumor growth and proliferation. Selumetinib is approved for symptomatic plexiform neurofibromas that are not amenable to surgical resection in patients with NF1. The gene discussed is MAP2K7; the disease is plexiform neurofibroma.